The Supply Lines: Which Companies are Making the News?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging. Which companies are making the news?

Companies making news at DCAT Week 2023 
The Drug, Chemical & Associated Technologies Association (DCAT) held its flagship event, DCAT Week, from March 19 to March 23, 2023, where bio/pharma companies and suppliers convened in New York for high-level business meetings, education programs featuring thought leaders, and networking events. With executives from the bio/pharma industry assembled, DCAT Member Companies took the opportunity to highlight recent news from across the bio/pharmaceutical manufacturing value chain.  

In the March 31, 2023, issue of DCAT Value Chain Insights, we featured companies taking to the podium at the DCAT Member Company Announcement Forum, where senior executives highlighted major news from their companies. Participating in the Forum were: Samsung Biologics, WuXi STA, Bachem, Siegfried, WuXi Biologics, Lonza, Catalent, Thermo Fisher Scientific, Flamma, Porton Pharma, BSP Pharmaceuticals, Granules, Meridian Medical Technologies/Kindeva Drug Delivery, and Incog BioPharma Services. See story, Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum for a roundup of their news announcements.  

In this issue, DCAT Value Chain Insights highlights other companies making the news in chemical/chemical API manufacturing, biologics manufacturing, formulation development and drug-product manufacturing, end-to-end manufacturing (both drug substances and drug products), and packaging. 

See related stories and the companies making the news below: 

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing featuring news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis, Avantor, Univar, Procos, Maithri Drugs, Dr. Reddy’s Laboratories, Jubilant Biosys, C2 Pharma, and ChemCon. 

From DCAT Week 2023: Supplier News: Biologics Manufacturing featuring news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. 

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing featuring news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical. 

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg with news from CordenPharma and BioDuro Sundia 

From DCAT Week 2023: Supplier News: Packaging featuring news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. 

Recent Feature Articles

Industry Roundtable: Small-Molecule APIs

By
What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What Trending: Biologic-Based Drugs

By
What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?

Upcoming DCAT European Conference: Expedition Pharma: Innovation from a Patient-First Perspective   

By
How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

The Bio/Pharma Majors’ Strategies & Products: Where Do Small-Molecule Drugs Rank?

By
How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may in store for 2025.